Barbara Gayle Duncan - Jun 24, 2022 Form 4 Insider Report for Jounce Therapeutics, Inc. (JNCE)

Role: Director
Signature: /s/ Caroline Gammill, Attorney-in-fact
Stock symbol: JNCE
Transactions as of: Jun 24, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/28/2022, 09:02 PM
Previous filing: Jun 21, 2022
Next filing: Jul 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JNCE	Stock Option (Right to Buy)	Award	$0	+20K		$0.00	20K	Jun 24, 2022	Common Stock	20K	$2.80	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2023 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors.

Content

The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2023 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors.